IBT's David Pinniger says biotechnology is the key to returns amid ageing and growing populations.
There has never been a better time to be investing in the global biotechnology sector. Investor risk appetite has been in steady decline over recent years, leaving this traditionally high-risk sector out of favour. Yet with growing and ageing populations, the value of innovative new drugs, diagnostics and medical devices to prevent and treat complex modern diseases more effectively has never been higher. While pharmaceutical companies are struggling to develop major new products from internal research and development (R&D) investment, biotechnology companies are demonstrating higher s...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
